Osteoporosis in prostate cancer patients

Authors

  • Choosak Pripatananont Division of Urology, Department of Surgery, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand

Keywords:

osteoporosis, prostate cancer

Abstract

-

Downloads

Download data is not yet available.

References

Vootiprux V. Penis and prostate. In: Sriplung H, Sontipong S, Wiangnon S, Vootiprux V, et al. eds. Cancer in Thailand Vol. 3 1995- 1997: Bangkok Medical Publisher 2003; 53-8.

Sriplung H. Annual incidence per 100,000 in male by age group ( years ) In: Sriplung H, Sontipong S, Wiangnon S, Vootiprux V, et al. eds. Cancer in Thailand Vol. 3 1995-1997: Bangkok Medical Publisher 2003; 158-9.

Gilsanz V. Accumulation of bone mass during childhood and adolescence. In :Orwell ES, ed. Osteoporosis in men. San Diego, Calif. Academic, 1999: 65-85.

Conde FA, Aronson WJ. Risk factors for male osteoporosis. Urologic Oncology: Seminars and original investigation. 2003; 21: 380-3.

National Institute of Health. Consensus Statement Number 4. Bethesda, MD: National Institute of Health, 1994.

Orwell ES. Osteoporosis in men. Endocrinol Metab Clin North Am 1998; 27: 349-65.

Jackson JA , Kleerekoper M. Osteoporosis in men : diagnosis, pathophysiology and prevention. Medicine 1990; 69: 137-41.

Campion JM , Maricic MJ. Osteoporosis in men . American Family Physician. 2003; 67: 1521-6.

Amin S, Felson DT. Osteoporosis in men. Rheum Dis Clin North Am 2001; 27: 19-47.

Smith MR. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology (supplement 3A) 2002; 60: 79-85.

Chang SS. Exploring the effects of luteinizing hormone-releasing hormone agonist therapy on bone health: implications in the management of prostate cancer. Urology (supplement 6A) 2003; 62: 29-35.

Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogen. J Clin Endocrinol Metab 1995; 80: 3689-98.

Oefelein MG, Resnick MI. Effective testosterone suppression for patients with prostate cancer: Is there a best castration ? Urology 2003; 62: 207-13.

Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J.Urol 2002 ; 167: 1952-6.

Diamond T, Campbell J, Bryant C, et al. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998; 83:1561-6.

Eriksson S, Eriksson A, Stege R, et al. Bone mineral Density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 1995; 57: 97-9.

Maillefert JF, Sibilia J, Michel F. et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999; 161: 1219-22.

Daniell HW, Dunn SR, Ferguson DW, et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181-6.

Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439-44.

Townsend MF, Sanders WH, Northway RO, et al. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostatic carcinoma. Cancer 1997; 79: 545-50.

Modi S, Wood L, Siminoski, et al. A comparison of the prevalence of osteoporosis and vertebral fractures in men with prostate cancer on various androgen deprivation therapies: preliminary report. Proc Am Soc Clin Oncol, suppl 2001; 167b.

Verhelst J, Denis L, Van Vliet P, et al. Endocrine profiles during administration of the new non-steroidal antiandrogen Casodex in prostate cancer. Clin Endocrinol 1994; 41: 525-30.

Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001; 57(1): 127-32.

Higano C, Stephens C, Nelson P, et al. Prospective serial measurements of bone mineral density in prostate cancer patients without bone metastases treated with intermittent androgen suppression. Proc Am Soc Clin Oncol, suppl 1999; 18: 314a abstract.

Giovannucci E, Rimm EB, Wolk A, et al. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 1998; 9: 567-82.

Chan JM, Stampfer MJ, Ma J, Gann PH, et al. Diary products,calcium,and prostate cancer risk in the physician health study. Am J Clin Nutr 2001; 74: 549-54.

Taxel P, Fall PM, Albertsen PC, et al. The effect of micronized oestradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 4907-13.

Reid IR, Brown JP, Burckhardt P, Horowitz Z, et al. Intravenous Zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-5.

Smith MR, Eastham J, Gleason DM, Shasha D ,et al. Randomized controlled trial of Zoledronic acid to prevent bone loss on men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-12.

Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94: 1458-68.

Downloads

Published

2005-06-01

How to Cite

Pripatananont, C. (2005). Osteoporosis in prostate cancer patients. Insight Urology, 26(S), 30–38. Retrieved from https://he02.tci-thaijo.org/index.php/TJU/article/view/253863

Issue

Section

Review article